TF and breast carcinoma: Thus, the lower SNA reactivity of anti-TF IgA antibodies (as evaluated by the SNA/IgA index), and their higher avidity demonstrated a rather good ability to discriminate patients with breast cancer from healthy controls already at the early stages of the disease.